THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific to Expand Access to Precision Oncology

01/18/2022 | 04:05pm EDT

Oncocyte Corporation announced a development and co-marketing agreement for two distributed in vitro diagnostic (IVD) assays on Thermo Fisher Scientific’s Ion Torrent™ Genexus™ System. The agreement also grants Oncocyte rights to develop future companion diagnostics on the Genexus System. Under the terms of the collaboration, Oncocyte will clinically validate Thermo Fisher’s existing Oncomine Comprehensive Assay Plus* on the Genexus System, paving the way toward IVD clearance for use in tumor profiling and future submissions as a companion diagnostic. As an IVD, the >500-gene assay will initially be able to provide physicians with information about patients’ tumors in accordance with established clinical evidence, applicable clinical trials, and future approval may assist with the selection of targeted therapies. Oncocyte will also develop its 27-gene expression DetermaIO™ test as a distributed kit on the Genexus. DetermaIO may predict response to immuno-oncology therapies based on data demonstrating potential pan-cancer utility and improvement over current standard-of-care tests.


ę S&P Capital IQ 2022
All news about THERMO FISHER SCIENTIFIC
05/11TRANSCRIPT : Thermo Fisher Scientific Inc. Presents at Bank of America 2022 Healthcare Con..
CI
05/11IonPath, Inc. announced that it has received funding from Thermo Fisher Scientific Inc.
CI
05/10Thermo Fisher Scientific Introduces QualTrak Biopharma qPCR Solutions to Streamline Bio..
CI
05/06THERMO FISHER SCIENTIFIC INC. Management's Discussion and Analysis of Financial Condit..
AQ
05/06Thermo Fisher Scientific to Present at BofA Securities 2022 Healthcare Conference
BU
05/06INSIDER SELL : Thermo Fisher Scientific
MT
05/05Interim report 1 January – 31 March 2022
AQ
05/04Thermo Fisher Scientific Inc. Launches Thermo Scientificdionex CR-CTC III Application W..
CI
04/29Morgan Stanley Adjusts Thermo Fisher Scientific's Price Target to $670 from $700, Keeps..
MT
04/28SECTOR UPDATE : Health Care Stocks Carried Higher in Thursday Markets Recovery
MT
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2022 42 581 M - -
Net income 2022 6 865 M - -
Net Debt 2022 25 677 M - -
P/E ratio 2022 31,3x
Yield 2022 0,22%
Capitalization 212 B 212 B -
EV / Sales 2022 5,58x
EV / Sales 2023 5,28x
Nbr of Employees 130 000
Free-Float 88,9%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 541,42 $
Average target price 669,21 $
Spread / Average Target 23,6%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
THERMO FISHER SCIENTIFIC-18.86%211 945
DANAHER CORPORATION-24.26%178 394
INTUITIVE SURGICAL, INC.-37.74%80 295
SIEMENS HEALTHINEERS AG-17.38%63 485
EDWARDS LIFESCIENCES CORPORATION-24.70%60 652
BOSTON SCIENTIFIC CORPORATION-6.64%56 697